Managed Account Advisors’s AstraZeneca AZN Stock Holding History

Managed Account Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$281M	Buy	4,415,683 +445,465	+11%	+$30.5M	0.23%	116
2015 Q1	$272M	Buy	3,970,218 +1,007,246	+34%	+$70M	0.24%	115
2014 Q4	$209M	Buy	2,962,972 +1,828,510	+161%	+$131M	0.21%	131
2014 Q3	$81M	Buy	1,134,462 +68,374	+6%	+$5M	0.09%	267
2014 Q2	$79.2M	Sell	1,066,088 -2,620,781	-71%	-$189M	0.1%	254
2014 Q1	$239M	Sell	3,686,869 -328,946	-8%	-$21.2M	0.31%	72
2013 Q4	$238M	Sell	4,015,815 -33,949	-0.8%	-$1.84M	0.32%	64
2013 Q3	$210M	Sell	4,049,764 -616,609	-13%	-$31M	0.31%	68
2013 Q2	$221M	Buy	+4,666,373	New	+$238M	0.34%	59

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Managed Account Advisors's AZN Position: Q2 2015 in Review

Managed Account Advisors increased its AstraZeneca (AZN) stake by 11% in Q2 2015, buying an estimated $30.5M and bringing the position to 4,415,683 shares worth $281M. The position accounts for 0.23% of the portfolio, ranked #116.

Managed Account Advisors first reported a position in AZN in Q2 2013 and has held it in 9 quarters since. 375 funds tracked by Wall St. Rank hold AZN as of Q2 2015.

Managed Account Advisors held 4,415,683 shares of AstraZeneca worth $281M as of Q2 2015.
Managed Account Advisors bought 445,465 AstraZeneca shares in Q2 2015, an estimated $30.5M.
AstraZeneca made up 0.23% of Managed Account Advisors's portfolio in Q2 2015, its #116 holding.
Managed Account Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 9 quarters since.
375 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.